- Home
- PGR vs SNY Comparison
PGR vs SNY Comparison
Compare PGR & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGR
- SNY
- Stock Information
- Founded
- PGR 1937
- SNY 1994
- Country
- PGR United States
- SNY France
- Employees
- PGR N/A
- SNY N/A
- Industry
- PGR Property-Casualty Insurers
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- PGR Finance
- SNY Health Care
- Exchange
- PGR Nasdaq
- SNY Nasdaq
- Market Cap
- PGR 120.8B
- SNY 116.1B
- IPO Year
- PGR N/A
- SNY N/A
- Fundamental
- Price
- PGR $227.12
- SNY $49.63
- Analyst Decision
- PGR Buy
- SNY Buy
- Analyst Count
- PGR 15
- SNY 4
- Target Price
- PGR $270.17
- SNY $61.50
- AVG Volume (30 Days)
- PGR 3.8M
- SNY 2.2M
- Earning Date
- PGR 10-15-2025
- SNY 10-24-2025
- Dividend Yield
- PGR 2.17%
- SNY 3.27%
- EPS Growth
- PGR 32.41
- SNY 105.93
- EPS
- PGR 18.22
- SNY 8.67
- Revenue
- PGR $85,166,000,000.00
- SNY $53,890,648,839.00
- Revenue This Year
- PGR $12.51
- SNY $2.37
- Revenue Next Year
- PGR $8.43
- SNY $6.51
- P/E Ratio
- PGR $12.40
- SNY $5.64
- Revenue Growth
- PGR 18.35
- SNY N/A
- 52 Week Low
- PGR $199.90
- SNY $44.62
- 52 Week High
- PGR $292.99
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- PGR 57.64
- SNY 45.86
- Support Level
- PGR $220.80
- SNY $48.73
- Resistance Level
- PGR $229.49
- SNY $52.67
- Average True Range (ATR)
- PGR 4.72
- SNY 0.73
- MACD
- PGR 2.27
- SNY -0.25
- Stochastic Oscillator
- PGR 91.45
- SNY 24.91
About PGR Progressive Corporation (The)
Progressive underwrites private and commercial auto insurance and specialty lines; it has almost 24 million personal auto policies in force and is one of the largest auto insurers in the United States. Progressive markets its policies through independent insurance agencies in the US and Canada and directly via the internet and telephone. Its premiums are split roughly equally between the agent and the direct channel. The company also offers commercial auto policies and entered homeowners insurance through an acquisition in 2015.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.